Revenue + Forward P/E
Regeneron Pharmaceuticals, Inc. (REGN) quarterly revenue and forward P/EForward P/E: 13.4x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$83.91B
Enterprise value
$67.33B
P/E ratio (TTM)
15.42x
P/S ratio (TTM)
4.53x
P/B ratio
2.17x
EV/Sales
4.51x
EV/EBITDA
11.72x
Dividend yield
0.55%
Income statement (TTM)
Revenue (TTM)
$14.34B
Gross profit (TTM)
$12.24B
Operating income (TTM)
$3.58B
EBITDA (TTM)
$5.82B
Net income (TTM)
$4.50B
Free cash flow (TTM)
$4.08B
Margins & returns
Gross margin
84.55%
Operating margin
24.32%
Profit margin
29.65%
Return on equity
14.32%
Return on assets
10.82%
Per-share metrics
EPS (TTM)
$42.53
Dividend yield
0.55%
Beta
0.24
Capital structure
Cash & equivalents
$3.12B
Total debt
$2.71B
Net debt
$-412.20M
Shares outstanding
103.02M
Financial health
Current ratio
4.13
Debt / equity
0.09
Debt / assets
0.07
Interest coverage
81.69
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $630.04B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $442.91B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $364.62B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.83B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $83.91B | 15.42x | 4.53x | 11.72x | 0.55% |